CSBio CSBio

X
[{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grifols' anti-SARS-CoV-2 Hyperimmune Globulin Begins Clinical Trial in Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Grifols International"},{"orgOrder":0,"company":"Grifols International","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grifols Announces Topline Data From NIAID Phase 3 ITAC Trial of Hyperimmune Globulins as A Treatment for Hospitalized Patients With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Grifols International"},{"orgOrder":0,"company":"Laboratorios Farmaceuticos Rovi","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and ROVI Announce Collaboration for OUS Fill-Finish Manufacturing of Moderna\u2019s COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SPAIN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Laboratorios Farmaceuticos Rovi"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spain's PharmaMar Says Covid-19 Treatment Drug Shows Clinical Efficacy in Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SPAIN","productType":"Peptide","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Peptide","graph2":"PharmaMar"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Life Science Alliance Journal Publishes Results of Plitidepsin in Patients With Covid-19, Which Includes Additional Data on Its Antiviral Activity Against Delta and Omicron Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SPAIN","productType":"Peptide","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Peptide","graph2":"PharmaMar"},{"orgOrder":0,"company":"Zendal","sponsor":"IAVI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Spanish Pharmaceutical Company Zendal and IAVI Partner to Advance the Tuberculosis Vaccine Candidate MTBVAC Into Efficacy Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SPAIN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Zendal"},{"orgOrder":0,"company":"Biofabri","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bharat Biotech and Biofabri Partner to Develop, Manufacture and Distribute a Novel TB Vaccine, MTBVAC","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SPAIN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Biofabri"},{"orgOrder":0,"company":"Biofabri","sponsor":"IAVI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zendal and IAVI Announce Expanded Agreement to Partner on Development of TB Vaccine Candidate MTBVAC","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SPAIN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Biofabri"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the agreement, IAVI is supporting development, global regulatory strategy, resource mobilization, and access planning for the adolescent/adult tuberculosis (TB) vaccine candidate MTBVAC.

            Lead Product(s): MTBVAC

            Therapeutic Area: Infections and Infectious Diseases Product Name: MTBVAC

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: IAVI

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement May 17, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            This agreement between BHARAT BIOTECH and BIOFABRI would guarantee the worldwide production and the supply of the future vaccine, MTBVAC in more than 70 countries with a high TB incidence, such as India, country with the highest TB burden in the world, with a 25% of all cases.

            Lead Product(s): MTBVAC,BCG Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: MTBVAC

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Bharat Biotech

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership March 16, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The final results of APLICOV-PC study (Phase I-II), demonstrate the safety of Aplidin (plitidepsin) use in patients with COVID-19 and postulate a positive therapeutic impact on the evolution of the disease.

            Lead Product(s): Plitidepsin

            Therapeutic Area: Infections and Infectious Diseases Product Name: Aplidin

            Highest Development Status: Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 11, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents and adults.

            Lead Product(s): Live Attenuated Mycobacterium Tuberculosis Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: MTBVAC

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: IAVI

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership July 14, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The APLICOV-PC study evaluated three cohorts of hospitalized patients with mild, moderate or severe disease, with three different dose levels of plitidepsin (1.5mg - 2.0mg - 2.5mg), administered on three consecutive days.

            Lead Product(s): Plitidepsin

            Therapeutic Area: Infections and Infectious Diseases Product Name: Aplidin

            Highest Development Status: Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 26, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (hIVIG) clinical trial, also known as INSIGHT-013 did not meet its primary endpoints with statistically significant results.

            Lead Product(s): Hyperimmune immunoglobulin,Remdesivir

            Therapeutic Area: Infections and Infectious Diseases Product Name: hIVIG

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 02, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            First international multicenter clinical trial of an anti-SARS-CoV-2 hyperimmune globulin and will include 500 hospitalized adults with COVID-19 in up to 58 hospitals in 18 countries. The therapy comes from the convalescent plasma of healthy people who have recovered COVID-19.

            Lead Product(s): Hyperimmune globulin

            Therapeutic Area: Infections and Infectious Diseases Product Name: ITAC

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 09, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            As part of the agreement, ROVI will provide vial filling and packaging capacity by procuring a new production line and equipment for compounding, filling, automatic visual inspection and labeling to support production of hundreds of millions of doses of Moderna's mRNA-1273.

            Lead Product(s): mRNA-1273

            Therapeutic Area: Infections and Infectious Diseases Product Name: mRNA-1273

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Moderna Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 09, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY